These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11940467)

  • 21. HER2 and response to paclitaxel in node-positive breast cancer.
    Ferretti G; Felici A; Cognetti F
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
    Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 and response to paclitaxel in node-positive breast cancer.
    Nash I
    N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
    [No Abstract]   [Full Text] [Related]  

  • 25. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):123-5; discussion 126-9. PubMed ID: 7481854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genentech's anticancer Mab expected by November.
    Robertson D
    Nat Biotechnol; 1998 Jul; 16(7):615. PubMed ID: 9661186
    [No Abstract]   [Full Text] [Related]  

  • 29. Single-agent paclitaxel for the treatment of breast cancer: an overview.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
    Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
    J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
    Seidman AD; Hudis CA; Raptis G; Baselga J; Fennelly D; Norton L
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):20-8. PubMed ID: 9110339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 35. Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.
    Lück HJ; Roché H
    Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S15-30. PubMed ID: 12505596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
    Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scheduling of taxanes: a review.
    Woodward EJ; Twelves C
    Curr Clin Pharmacol; 2010 Aug; 5(3):226-31. PubMed ID: 20406166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
    Miller KD
    Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
    [No Abstract]   [Full Text] [Related]  

  • 39. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.
    Bader AA; Schlembach D; Tamussino KF; Pristauz G; Petru E
    Lancet Oncol; 2007 Jan; 8(1):79-81. PubMed ID: 17196514
    [No Abstract]   [Full Text] [Related]  

  • 40. Weekly administration of paclitaxel: theoretical and clinical basis.
    Marchetti P; Urien S; Cappellini GA; Ronzino G; Ficorella C
    Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S3-13. PubMed ID: 12505595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.